Title |
Might dolutegravir be part of a functional cure for HIV?1
|
---|---|
Published in |
Canadian Journal of Microbiology, January 2016
|
DOI | 10.1139/cjm-2015-0725 |
Pubmed ID | |
Authors |
Mark A. Wainberg, Ying-Shan Han, Thibault Mesplède |
Abstract |
Antiretroviral therapy (ART) has greatly decreased HIV-related morbidity and mortality. However, HIV can establish viral reservoirs that evade both the immune system and ART. Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) related to the first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG). DTG shows a higher genetic barrier to the development of HIV-1 resistance than RAL and EVG. More interestingly, clinical resistance mutations to DTG in treatment-naïve patients have not been observed to date. This review summarizes recent studies on strategies toward a cure for HIV, explores resistance profiles of DTG, and discusses how DTG might help in finding a functional cure for HIV. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 2% |
Portugal | 1 | 2% |
Unknown | 49 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 16% |
Student > Master | 8 | 16% |
Student > Bachelor | 7 | 14% |
Other | 5 | 10% |
Researcher | 4 | 8% |
Other | 7 | 14% |
Unknown | 12 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 16 | 31% |
Agricultural and Biological Sciences | 6 | 12% |
Immunology and Microbiology | 5 | 10% |
Biochemistry, Genetics and Molecular Biology | 4 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Other | 2 | 4% |
Unknown | 16 | 31% |